Key result
Serum ACE levels may accurately stage liver fibrosis in chronic hepatitis B.
Why the study?
Serum ACE levels may serve as a non-invasive biomarker to evaluate fibrosis stages related to chronic hepatitis B, but their clinical utility requires clarification.
Does serum ACE level measurement accurately detect stages of liver fibrosis in patients with CHB?
Does serum ACE level measurement accurately detect stages of liver fibrosis in patients with CHB?
Serum ACE levels may serve as an accurate, non-invasive biomarker for evaluating liver fibrosis stages in chronic hepatitis B.
May support non-invasive fibrosis monitoring in CHB; hypothesis-generating for RAS inhibition.
, Noguchi et al showed the predictive value of serum ACE levels in detecting not only advanced stages of liver fibrosis but also initial and intermediate fibrotic stages. The serum levels of ACE might represent an accurate, non-invasive, widely available, and easy method to evaluate fibrosis related to CHB. Moreover, therapies involving the inhibition of the classical RAS axis components might be promising in the control of CHB-related liver fibrosis.
No takes yet. Share an insight, caveat, or question.
Miranda et al. (2017) conducted an editorial in CHB-related liver fibrosis. Serum angiotensin converting enzyme (ACE) levels was evaluated on Detection of liver fibrosis stages. Serum ACE levels may serve as an accurate, non-invasive biomarker to evaluate initial, intermediate, and advanced stages of liver fibrosis related to chronic hepatitis B.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: